Kennedy Capital Management, Inc. Verastem, Inc. Transaction History

Kennedy Capital Management, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$6.86 - $9.97 $1.25 Million - $1.82 Million	-182,443 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$2.88 - $8.67 $8,631 - $25,983	-2,997 Reduced 1.62%	182,443 $1.26 Million
Q1 2018 May 14, 2018	BUY	$2.92 - $3.81 $541,484 - $706,526	185,440 New	185,440 $553,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $838M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.